Paroxetine use in pregnancy and increased risk of heart defects: Evaluating the evidence

Canadian Family Physician

Volumn 56, Issue 8, 2010, Pages 767-768

  Adrienne, Einarson ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE;

ANXIETY DISORDER; CONGENITAL HEART MALFORMATION; DEPRESSION; DISEASE SEVERITY; DRUG INFORMATION; DRUG SAFETY; FIRST TRIMESTER PREGNANCY; HUMAN; PREGNANCY; PREGNANCY OUTCOME; REVIEW; RISK ASSESSMENT;

ABNORMALITIES, DRUG-INDUCED; ADULT; DEPRESSION; EVIDENCE-BASED MEDICINE; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; META-ANALYSIS AS TOPIC; PAROXETINE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, FIRST; SEROTONIN UPTAKE INHIBITORS; UNCERTAINTY;

EID: 77956521907     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 2005;14(12):823-7. (Pubitemid 43056107)
2. Wen SW, Yang Q, Garner P, Fraser W, Olatunbosun O, Nimrod C, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006;194(4):961-6.
3. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005;106(6):1289-96. (Pubitemid 41668948)
4. GlaxoSmithKline. Use of paroxetine in first trimester of pregnancy may have a small increased risk of birth defects, compared to other antidepressants. October 2005. Mississauga, ON: GlaxoSmithKline; 2005. Available from: www.hc-sc.gc.ca/dhp-mps/alt-formats/hpfb-dgpsa/pdf/medeff/paxil-3-pa-ap-eng.pdf. Accessed 2010 Jun 8.
5. Cole JA, Ephross SA, Cosmatos IS, Walker AM. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007;16(10):1075-85.
6. Källén BA, Otterblad Olausson P. Maternal use of selective serotonin reuptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007;79(4):301-8.
7. Diav-Citrin O, Shechtman S, Weinbaum D, Arnon J, Di Gianantonio E, Clementi M, et al. Paroxetine and fluoxetine in pregnancy: controlled study [abstract]. Reprod Toxicol 2005;20(3):459.
8. Health Canada [website]. Health Canada endorsed important safety information on Paxil (paroxetine). December 16, 2005. Ottawa, ON: Health Canada; 2005. Available from: www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/- 2005/paxil-4-hpc-cps-eng.php. Accessed 2010 Jul 9.
9. Einarson A, Pistelli A, DeSantis M, Malm H, Paulus WE, Panchaud A, et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 2008;165(6):749-52. Epub 2008 Apr 1.
10. Wurst KE, Poole C, Ephross SA, Olshan AF. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 2010;88(3):159-70.
11. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009;339:b3569. DOI: 10.1136/bmj.b3569.
12. Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010 Jan 5. Epub ahead of print.
13. Bakker MK, Kerstjens-Frederikse WS, Buys CH, de Walle HE, de Jong-van den Berg LT. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol 2010;88(2):94-100.
14. Wurst KE, Poole C, Ephross SA, Olshan AF. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a metaanalysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 2010;88(3):159-70.
15. Bérard A. Paroxetine exposure during pregnancy and the risk of cardiac malformations: what is the evidence? Birth Defects Res A Clin Mol Teratol 2010;88(3):171-4.
16. Scialli AR. Paroxetine exposure during pregnancy and cardiac malformations. Birth Defects Res A Clin Mol Teratol 2010;88(3):175-7.
17. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol 2002;39(12):1890-900.
18. Einarson A. Studying the safety of drugs in pregnancy: and the gold standard is.... J Clin Pharmacol Pharmacoepidemiol 2008;1:3-8.